Case Study: Making Radiology AI Safe, Traceable, and Clinically Sustainable - A case for AI medical-device developers, imaging providers, and regulatory teams

Executive summary

Radiology has become the leading clinical domain for artificial intelligence-enabled medical devices, but regulatory authorization alone does not ensure that an algorithm will be safe, useful or economically sustainable in every clinical environment. An AI tool may perform well in a development dataset and still encounter materially different scanners, protocols, patient populations, prevalence patterns, reporting conventions and user behaviors after deployment. At the same time, developers must maintain coherent design controls and evidence as products evolve, providers must decide whether a tool is appropriate for local use, and regulatory teams must preserve traceability across updates, complaints, corrective actions and postmarket signals.

E&E Regulatory Assurance addresses this fragmented operating model. The platform creates one controlled record that connects the product claim to requirements, risks, datasets, verification and validation evidence, submission content, deployment controls and postmarket performance. It serves three groups through role-specific views: the developer preparing and maintaining the medical device; the hospital or imaging center evaluating and operating it; and the E&E consultant providing regulatory and quality oversight. Each group sees the decisions relevant to its work, while the underlying evidence and audit history remain shared and traceable.

In the representative case described here, a radiology AI developer and a regional imaging network prepare a CT triage application for regulatory submission and controlled clinical introduction. Before using the platform, the parties rely on disconnected spreadsheets, document repositories, email approvals and local dashboards. The same intended-use statement appears in multiple places; evidence is difficult to reconcile with specific risks; site acceptance testing is planned late; and postmarket measures are not linked to premarket assumptions. E&E Regulatory Assurance restructures the initiative around a six-stage lifecycle: Assess, Design, Validate, Submit, Deploy and Monitor & Improve.

The result is not an automated promise of compliance. It is a safer system of work. Qualified people remain accountable for regulatory, clinical and quality decisions. The platform makes those decisions easier to prepare, review, challenge and defend by exposing missing evidence, preventing uncontrolled changes, maintaining version history and measuring whether the deployed system continues to operate within approved and locally accepted boundaries.

The radiology AI problem is a lifecycle problem

Radiology AI is often purchased or developed as though diagnostic performance were the entire product. Sensitivity, specificity, area under the curve and reading-time improvement are important, but they are only a portion of the assurance case. The real product is a socio-technical system: images are acquired under varying protocols; data move through DICOM, PACS, RIS and EHR infrastructure; models generate outputs; interfaces prioritize or display those outputs; radiologists interpret them; downstream teams act; and governance groups decide whether observed performance remains acceptable.

This system creates several recurring failure modes. First, the clinical claim can drift away from the evidence. Marketing language, protocol objectives, labeling and user expectations may describe subtly different uses. Second, risks are documented without a direct line to mitigations and proof. A false negative may be listed in a risk file, yet the evidence supporting its control may live in an unrelated report. Third, local deployment introduces conditions that were not fully represented during development. Fourth, model and software changes can outpace the documentation needed to evaluate their regulatory impact. Finally, performance monitoring may focus on uptime and volume while missing subgroup behavior, discordant cases, alert fatigue or workflow workarounds.

Current regulatory and professional direction reinforces the need for a total product lifecycle approach. FDA’s Good Machine Learning Practice materials emphasize safe, effective and high-quality AI/ML devices across the lifecycle. FDA’s 2025 final guidance on predetermined change control plans describes how planned modifications, modification protocols and impact assessments can support iterative improvement while maintaining reasonable assurance of safety and effectiveness. In 2026, the American College of Radiology and the Society for Imaging Informatics in Medicine advanced a practice parameter covering AI selection, predeployment evaluation, ongoing monitoring and continuous quality improvement. The direction is clear: responsible adoption is an operating discipline, not a one-time clearance event.

OPPORTUNITY: The market needs connective tissue between regulated product development and real-world clinical governance. That is the role E&E Regulatory Assurance is designed to fill.

The representative organization and its challenge

The composite case involves Northstar Imaging Network, a fictional regional provider operating one hospital-based radiology department and four outpatient imaging centers, and Vela Imaging AI, a fictional developer of software that flags suspected acute findings on head CT for worklist prioritization. E&E Medicals and Consulting supports both organizations through a defined regulatory-assurance engagement. Northstar wants faster escalation of time-sensitive studies without increasing false alerts or creating an unmanageable oversight burden. Vela wants a submission-ready evidence package and a disciplined method for controlling future model and workflow changes.

At project start, neither organization lacks effort or expertise. The difficulty is fragmentation. Vela maintains requirements in a spreadsheet, risks in a separate application, datasets in technical notebooks, testing results in document files and submission drafts in shared folders. Northstar has an AI governance committee but no standard process for translating a vendor’s authorized intended use into site-specific acceptance criteria. Procurement, radiology, IT security, clinical engineering and compliance ask overlapping questions in different formats. Important decisions are recorded in meeting notes rather than linked to the affected control.

The fragmentation produces four business consequences. Reviews take longer because people repeatedly reconstruct context. Gaps appear late, when they are expensive to repair. Provider confidence depends too heavily on vendor presentations instead of locally governed evidence. And neither party has a shared plan for what happens after go-live if scanner mix, patient mix, software versions or clinical behavior change. The project needs a single assurance layer that respects organizational boundaries while preserving a defensible chain of evidence.

The E&E Regulatory Assurance solution

E&E Regulatory Assurance is configured as a compliance-native workspace rather than a diagnostic engine. It does not interpret images or replace a radiologist. It coordinates the evidence, controls, decisions and monitoring that surround AI-enabled radiology products. Every product begins with a controlled profile containing its intended use, users, patient population, modality, clinical setting, input characteristics, output, workflow role and current regulatory pathway assumption. That profile becomes the reference point for downstream requirements and reviews.

The platform then creates a connected assurance graph. Clinical and technical requirements are linked to identified hazards and hazardous situations. Risk controls are linked to verification or validation evidence. Datasets are characterized by source, inclusion criteria, exclusions, labeling method, scanner and protocol mix, demographic coverage and separation between training and evaluation. Submission sections reference the approved evidence objects rather than uncontrolled copies. Deployment packages inherit the authorized product version and intended-use boundaries. Postmarket signals retain links to the requirements, risks and acceptance thresholds that made them meaningful in the first place.

Role-specific experiences, one source of truth

Vela’s developer view emphasizes design controls, evidence readiness, unresolved traceability, cybersecurity documentation, labeling alignment and change-impact assessment. Northstar’s provider view emphasizes vendor evidence, local acceptance testing, privacy and security review, workflow configuration, human oversight, stop rules and performance monitoring. The E&E consultant view spans the lifecycle, presenting readiness gates, open findings, accountable owners and the rationale behind recommendations. Permissions limit who can create, approve or retire controlled objects, while the audit trail records relevant changes and decisions.

This separation is important. A provider should not be able to silently alter a manufacturer’s intended use, and a manufacturer should not be able to mark a hospital’s local clinical acceptance complete. The platform allows the two assurance cases to meet without collapsing their responsibilities. E&E consultants facilitate that boundary, identify inconsistencies and confirm that required reviews are performed by authorized people.

Regulatory guardrails by design

The platform uses guarded language and structured review states. It can identify that evidence appears incomplete against a configured checklist, but it does not declare a device FDA compliant. It can propose that a change may require regulatory assessment, but it does not independently determine the legally binding pathway. It can calculate a readiness score from defined controls, but the score is never represented as an FDA rating. Each recommendation exposes its basis, applicable product version and outstanding assumptions. Final regulatory, clinical and quality decisions require named human approval.

Implementation across the six-stage lifecycle

Stage 1: Assess the use case and regulatory boundary

E&E begins by converting the business idea into a precise product and workflow statement. The team records what the AI detects or prioritizes, who sees the output, when it appears, how it influences care and what action remains with the radiologist. Comparable devices and likely submission pathways are assessed, but assumptions remain visibly provisional until confirmed. The platform also creates an initial value hypothesis, including expected operational benefits, possible new workload, downstream consequences and the metrics required to judge success.

For Northstar and Vela, this stage reveals an ambiguity: some stakeholders describe the tool as diagnostic, while the planned labeling describes triage and prioritization. Resolving that ambiguity early prevents protocol endpoints, user-interface copy and training materials from implying a broader claim than the evidence strategy supports.

Stage 2: Design the assurance architecture

The team decomposes the intended use into clinical, software, data, usability, interoperability, security and quality requirements. A risk analysis covers erroneous output, delayed output, unavailable output, incorrect patient or study association, automation bias, alert fatigue and foreseeable misuse. Each control is assigned an owner and required evidence. Human factors are treated as a safety mechanism: radiologists must understand the role and limitations of the output, maintain access to the underlying study and retain final interpretive authority.

The platform flags orphaned risks without controls, controls without verification and requirements not represented in planned testing. Review gates prevent design freeze while critical traceability gaps remain unresolved. Instead of discovering these issues during submission assembly, Vela addresses them while the architecture and protocols are still adaptable.

Stage 3: Validate performance in context

Validation combines technical performance with clinical and workflow evidence. The platform records dataset provenance and independence, reference-standard construction, missing-data rules, subgroup definitions and planned statistical analyses. It separates evidence supporting the manufacturer’s claim from Northstar’s local acceptance work. This distinction avoids treating a small local sample as a substitute for formal device validation while still recognizing that the provider must understand performance and workflow behavior in its environment.

Northstar defines acceptance tests for routing accuracy, latency, user access, display behavior, downtime handling and representative local cases. Results are tied to scanner type, protocol, site and product version. Discordant cases receive documented review. If a threshold is missed, the platform opens a finding with containment, investigation and disposition rather than allowing the result to disappear into a meeting presentation.

Stage 4: Assemble and control the submission

Once evidence is approved, the submission workspace assembles a readiness view across device description, intended use, software documentation, risk management, cybersecurity, performance testing, human factors, labeling and change-control planning. The objective is not auto-authoring a submission from generic text. It is ensuring that every claim in the submission is supported by the correct controlled evidence and that contradictions are visible before filing.

For planned AI modifications, Vela can maintain a structured PCCP workspace describing the scope of anticipated modifications, the methods used to develop, validate and implement them, and the impact assessment. The workspace supports preparation under FDA guidance, while E&E’s qualified reviewers decide how the guidance applies to the specific device and submission.

Stage 5: Deploy under local governance

After authorization and contracting, Northstar activates a site-assurance package for the released product version. It includes inventory information, intended-use boundaries, responsible owners, technical acceptance results, user training, communication and escalation procedures, downtime behavior, monitoring thresholds and stop rules. Go-live cannot be represented as complete until the provider’s authorized reviewers approve the defined gates.

This stage closes a common gap between procurement and clinical operations. Northstar can show which version is operating at each site, which interfaces are active, which populations and workflows are in scope, and what evidence supported the deployment decision. Vela can see provider-reported technical and safety issues without controlling the provider’s local governance record.

Stage 6: Monitor, learn and improve

The monitoring plan combines technical reliability, clinical performance proxies, user behavior and quality-system signals. Measures may include output availability, processing latency, alert prevalence, radiologist concordance, override or dismissal patterns, subgroup performance, complaint trends, reportable-event assessment and CAPA status. Thresholds are versioned and linked to a response plan. When a signal crosses a threshold, the platform records triage, investigation, containment, root cause, corrective action and effectiveness review.

Monitoring also informs future change. A proposed model update is assessed against the authorized device, the approved PCCP where applicable, affected hazards, new evidence and site revalidation needs. This creates a closed loop: real-world evidence does not merely populate a dashboard; it becomes controlled input to product and governance decisions.

Expected value and measurable outcomes

Because this is a representative case, the value proposition should be tested through defined pilot measures rather than asserted as accomplished fact. E&E would establish baselines before implementation and measure changes after adoption. The first category is regulatory execution: time spent locating evidence, number of unresolved traceability gaps at review gates, review-cycle duration, submission rework and time required to assess a proposed change. The second is provider assurance: time from contract to governed go-live, completion of acceptance tests, training completion, number of undocumented AI tools or versions and time to investigate a site signal.

The third category is safety and clinical sustainability. Measures include the proportion of monitored studies with complete contextual data, concordance and discordance trends, subgroup coverage, alert burden, user-reported workflow issues, stop-rule events and closure time for investigations. The fourth category is economic value: avoided duplicate review effort, reduced manual audit preparation, faster evidence reuse, downstream workflow impact and the cost of operating the governance program.

PILOT SUCCESS DEFINITION : The platform succeeds when it reduces uncertainty and rework while increasing the completeness, speed and defensibility of human decisions—not when it produces the highest automated readiness score.

An executive dashboard can summarize these measures, but the defensible asset is the evidence beneath them. A readiness percentage must disclose which controls are included, how they are weighted, which items are blocked and who approved completion. A performance trend must identify the algorithm version, site, study population, time window and reference method. This transparency prevents attractive dashboards from becoming another source of unexamined risk.

Why the model differentiates E&E Medicals

Most radiology AI offerings compete through algorithms, marketplaces, reporting automation or workflow orchestration. E&E’s differentiated position is assurance across organizational boundaries. Its regulatory and quality expertise is embedded into the structure of the work: the relationship between claims and evidence, the gates that require review, the preservation of version history and the transition from premarket assumptions to postmarket measurement.

This model is defensible because it can develop a regulatory knowledge layer and a real-world assurance benchmark without owning the diagnostic algorithm. Over time, de-identified and appropriately governed implementation data could help E&E understand recurring readiness gaps, validation patterns, workflow risks and operating thresholds across products and sites. Those insights could improve assessment templates and benchmarking while preserving customer confidentiality and complying with applicable privacy, security and data-use obligations.

The model also aligns incentives. Developers receive a clearer route to evidence readiness and managed change. Providers receive independent structure for evaluation and ongoing governance. E&E receives a recurring role beyond a one-time submission project. The platform becomes the operating environment through which regulatory strategy, quality management, deployment assurance and continuous improvement remain connected.

Deployment roadmap and controls

A prudent launch would proceed in three increments. The first is a controlled advisory workspace using synthetic or non-sensitive project data. It should support product profiles, requirements, risks, evidence links, review gates, role permissions and audit history. The second introduces controlled document storage, electronic approvals, complaint and CAPA workflows, site acceptance testing and validated readiness calculations. The third integrates selected PACS, RIS, EHR, quality and monitoring data sources, supported by formal interface validation and security controls.

Production readiness requires more than feature completion. E&E should define the platform’s own intended purpose and determine which functions are administrative, quality-system enabling or potentially subject to medical-device regulation. It should operate a quality management system appropriate to the product and claims; apply software lifecycle, risk-management, cybersecurity, privacy and human-factors practices; validate regulated and quality-critical workflows; maintain access controls and immutable audit records; and establish procedures for backup, recovery, incident response, supplier management and change control.

The platform should never create unsafe confidence through language such as “FDA approved,” “guaranteed compliant” or “clinically validated” unless those statements are accurate for the specific object and supported by evidence. Generated recommendations should be labeled as decision support, expose their source and assumptions, and route consequential determinations to qualified reviewers. AI used inside the platform to summarize documents or suggest mappings should be constrained, logged and independently verified before it affects a controlled record.

Conclusion: from clearance event to assurance system

Radiology AI can improve care only when strong algorithms operate inside strong systems. Authorization is necessary for regulated devices, but clinical trust is earned through disciplined selection, validation, integration, human oversight, monitoring and improvement. Developers, providers and consultants currently perform much of this work through fragmented tools that obscure dependencies and force teams to reconstruct the same evidence repeatedly.

E&E Regulatory Assurance offers a different model. It turns regulatory strategy and clinical governance into a connected lifecycle. The developer’s design evidence, the provider’s local assurance and the consultant’s regulatory judgment remain distinct but traceable. Every material claim can be linked to requirements, risks and evidence. Every release and deployment can be identified. Every signal can be investigated against the assumptions and controls that preceded it.

The platform’s promise is therefore not that software can make radiology AI “FDA safe” by itself. Safety and compliance are outcomes of accountable organizations, qualified people, appropriate evidence and controlled processes. E&E Regulatory Assurance makes that system of responsibility visible, executable and measurable. In a market crowded with algorithms, E&E can differentiate by becoming the trusted assurance layer that helps radiology AI move from promising technology to safe, sustainable clinical practice.

Sources and regulatory context

U.S. Food and Drug Administration. Artificial Intelligence-Enabled Medical Devices; current device-list context and transparency statements. https://www.fda.gov/medical-devices/software-medical-device-samd/artificial-intelligence-enabled-medical-devices

U.S. Food and Drug Administration. Good Machine Learning Practice for Medical Device Development: Guiding Principles. https://www.fda.gov/medical-devices/software-medical-device-samd/good-machine-learning-practice-medical-device-development-guiding-principles

U.S. Food and Drug Administration. Marketing Submission Recommendations for a Predetermined Change Control Plan for Artificial Intelligence-Enabled Device Software Functions, final guidance, August 2025. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/marketing-submission-recommendations-predetermined-change-control-plan-artificial-intelligence

American College of Radiology. ACR Approves First Practice Parameter for Imaging Artificial Intelligence, May 5, 2026. https://www.acr.org/News-and-Publications/Media-Center/2026/first-practice-parameter-for-imaging-ai

American Medical Association. CPT Appendix S: Artificial Intelligence Taxonomy for Medical Services and Procedures. https://www.ama-assn.org/practice-management/cpt/cpt-appendix-s-taxonomy-artificial-intelligence-medical-services-procedures

‍